Access cutting-edge allogeneic stem cell transplantation treatment through this phase 3 clinical trial at a research site in Bethesda. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Bethesda location
Preparing your pre-screening questions…
Access allogeneic stem cell transplantation specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related allogeneic stem cell transplantation treatment provided free
Check if you qualify for this allogeneic stem cell transplantation clinical trial in Bethesda, MD
No-Cost Study Care
Local to Bethesda
Convenient for MD residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Background: Injury or diseases of the heart and lung can sometimes cause scar tissue (fibrosis) to build up in those organs. Current imaging scans can see this scar tissue once it has formed, but researchers want to find a way to detect the fibrosis in its earliest stages, while there might still be time to prevent serious damage. A new tracer (a radioactive substance injected during imaging scans) may be able to help. Objective: To test a new tracer (18F-FAPI-74) during imaging scans in people with heart or lung disease. Eligibility: People aged 18 years and older with lung or heart disease that may cause scarring in those organs. Design: Participants will have 6 clinic visits over 2 years. Participants will be screened: They will have blood tests and tests of their heart and lung function. Those with heart disease will have a magnetic resonance imaging (MRI) scan of the heart. The study tracer will be used with positron emission tomography (PET)/computed tomography (CT) scans. The study tracer will be injected into a vein in the arm. Participants will lie on a padded bed that slides through a donut-shaped machine. Participants will have scans with the study tracer 2 times, 8 to 12 months apart. They will also have standard CT scans and blood tests during these visits. They will also have blood tests at 3 and 6 months between these visits. Participants will have a follow-up visit after 18 to 24 months. The study scans, MRI and standard CT scans, and lung function tests may be repeated....
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Yes, this clinical trial (NCT07613099) has an active research site in Bethesda, MD that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for allogeneic stem cell transplantation treatment options in Bethesda, MD, this clinical trial (NCT07613099) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Bethesda research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced allogeneic stem cell transplantation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all allogeneic stem cell transplantation clinical trials near you to find additional studies recruiting in your area.
See all leukemia clinical trials recruiting in Bethesda — not just this study.
Browse Leukemia Trials in Bethesda →